MARK2 and metabolic dysfunction-associated steatohepatitis: Recent reports from phase 2 clinical trials in patients with non-alcoholic steatohepatitis (NASH) showed reduced liver fibrosis when targeting macrophages using the inhibitor of the serine/threonine kinase ASK1, selonsertib [41], or the dual CCR2/CCR5 inhibitor cenicriviroc [42].